EYPT EyePoint Pharmaceuticals, Inc.
Healthcare$13.35+3.25%ClosedMarket Cap: $1.12B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.82
P/S
142.36
EV/EBITDA
-3.69
DCF Value
$-2.83
FCF Yield
-25.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.5%
Operating Margin
-3700.9%
Net Margin
-3566.6%
ROE
-110.5%
ROA
-94.2%
ROIC
-112.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $696.0K | 24.1% | $-87.2M | $-84.8M | $— | — |
| Q4 null | $620.0K | 39.5% | $-70.3M | $-67.6M | $— | — |
| FY null | $31.4M | 93.4% | $-243.4M | $-232.0M | $— | — |
| Q3 null | $966.0K | 25.4% | $-62.0M | $-59.7M | $— | — |
| Q2 null | $5.3M | 96.9% | $-62.2M | $-59.4M | $— | — |
| Q1 null | $24.5M | 96.7% | $-48.8M | $-45.2M | $— | — |
| Q4 null | $11.6M | 93.0% | $-45.2M | $-41.4M | $— | — |
| FY null | $43.3M | 91.4% | $-145.9M | $-130.9M | $— | — |
| Q3 null | $10.5M | 93.0% | $-32.7M | $-29.4M | $— | — |
| Q2 null | $9.5M | 85.2% | $-34.5M | $-30.8M | $— | — |
| Q1 null | $11.7M | 93.5% | $-33.3M | $-29.3M | $— | — |
| Q4 2023 | $14.0M | 92.9% | $-16.4M | $-14.1M | $-0.33 | — |